Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category

The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.

By Meagan Parrish • March 8, 2024

Amylyx ALS drug fails crucial study, putting company’s future in doubt

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

By Jacob Bell • Updated March 8, 2024

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

By Michael Gibney • March 5, 2024

Biogen partner NeuroSense seeks a role in the ALS revolution

Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

By Michael Gibney • Feb. 29, 2024

Can a top scientist and Moderna co-founder change the CRO game?

From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

By Michael Gibney • Feb. 28, 2024

A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain

How research companies can shift strategies to attract and retain the staff that keeps trials humming along. 

By Kelly Bilodeau • Feb. 28, 2024

BioMarin preaches patience amid slow sales for hemophilia gene therapy

The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

By Ben Fidler • Feb. 23, 2024

For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

By Amy Baxter • Feb. 23, 2024

AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

By Michael Gibney • Feb. 22, 2024

Biden or Trump: How deeply will 2024’s election outcome impact pharma?

The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

By Michael Gibney • Feb. 20, 2024

Pharma CFOs need R&D vigilance in tough economic times

Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

By Amy Baxter • Feb. 16, 2024

The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

By Michael Gibney • Feb. 15, 2024

‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

By Michael Gibney • Feb. 14, 2024

FDA inches closer to defining its regulatory role in AI

Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

By Amy Baxter • Feb. 12, 2024

Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

By Michael Gibney • Feb. 8, 2024

Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

By Alexandra Pecci • Feb. 6, 2024

Vaxxinity is brewing up meds for a spacefaring future

The biotech’s bone- and muscle-building treatments could someday help humans reach other planets. 

By Kelly Bilodeau • Feb. 5, 2024

Merck keeps deal focus with Keytruda patent cliff on horizon

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

By Ned Pagliarulo • Feb. 1, 2024

Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.

By Michael Gibney • Feb. 1, 2024

Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.  

By Michael Gibney • Jan. 31, 2024

‘1 plus 1 equals 3’ — the co-CEO model in pharma

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

By Meagan Parrish • Jan. 26, 2024

The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.

By Michael Gibney • Jan. 24, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

FDA chief says agency can’t manage health tech alone

FDA Commissioner Dr. Robert Califf recently spoke about the future of AI and machine learning and the need for constant vigilance to improve healthcare systems.

By Alexandra Pecci • Jan. 16, 2024